Chapman PB - Search Results

1

Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy.

Wolchok JD, Klimek VM, Williams L, Chapman PB. Wolchok JD, et al. Among authors: chapman pb. Cytokines Cell Mol Ther. 1999 Dec;5(4):205-6. Cytokines Cell Mol Ther. 1999. PMID: 10850383

2

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.

Eton O, Bajorin DF, Chapman PB, Cody BV, Houghton AN. Eton O, et al. Among authors: chapman pb. Invest New Drugs. 1991 Feb;9(1):101-3. doi: 10.1007/BF00194558. Invest New Drugs. 1991. PMID: 2026478 Clinical Trial.

3

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.

Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. Minasian LM, et al. Among authors: chapman pb. Cancer. 1995 May 1;75(9):2251-7. doi: 10.1002/1097-0142(19950501)75:9<2251::aid-cncr2820750910>3.0.co;2-f. Cancer. 1995. PMID: 7536122 Clinical Trial.

4

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.

Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Sirott MN, et al. Among authors: chapman pb. Cancer. 1993 Nov 15;72(10):3091-8. doi: 10.1002/1097-0142(19931115)72:10<3091::aid-cncr2820721034>3.0.co;2-v. Cancer. 1993. PMID: 8221576

5

Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma.

Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, Williams L, Nathan CF, Houghton AN. Minasian LM, et al. Among authors: chapman pb. Blood. 1994 Jan 1;83(1):56-64. Blood. 1994. PMID: 8274754 Free article. Clinical Trial.

6

Medical treatment of metastatic melanoma.

Houghton AN, Meyers ML, Chapman PB. Houghton AN, et al. Among authors: chapman pb. Surg Clin North Am. 1996 Dec;76(6):1343-54. doi: 10.1016/s0039-6109(05)70519-3. Surg Clin North Am. 1996. PMID: 8977555 Review.

7

Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.

Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J. Soiffer RJ, et al. Among authors: chapman pb. Clin Cancer Res. 1997 Jan;3(1):17-24. Clin Cancer Res. 1997. PMID: 9815532 Clinical Trial.

8

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.

Jakubowski AA, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN. Jakubowski AA, et al. Among authors: chapman pb. Clin Cancer Res. 1996 Feb;2(2):295-302. Clin Cancer Res. 1996. PMID: 9816172 Clinical Trial.

9

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. McCaffery M, et al. Among authors: chapman pb. Clin Cancer Res. 1996 Apr;2(4):679-86. Clin Cancer Res. 1996. PMID: 9816218 Clinical Trial.

10

Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.

Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, Houghton AN, Chapman PB. Nasi ML, et al. Among authors: chapman pb. Cytokines Cell Mol Ther. 1999 Sep;5(3):139-44. Cytokines Cell Mol Ther. 1999. PMID: 10641571 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters